GaPP2 Trial

Gapp2 Home Header

facebook

twitter
youtube
Please Follow Us On Our Social Media Channels.

Study details:

Full Title: A multi-centre randomised controlled trial of the efficacy and mechanism of action of gabapentin for the management of chronic pelvic pain in women

Short Title: 
GaPP2

Aims of the study: 
Chronic pelvic pain affects over 1 million women in the UK. It is the reason for 20% of gynaecological consultations and it causes a 45% reduction in work productivity. For women who have no cause for their pain, finding an effective treatment can be problematic and there are no proven treatments available. The main aim of the study is to see if  gabapentin will reduce pain in women with long-term pelvic pain and therefore increase their quality of life.

Study design: 
A double blind randomised controlled trial.

Sample size: 
300 participants to recruit over 21 months.

Study Duration: 
The accrual period is for 21 months and all patients in the main study will be followed up for 12 weeks. 

Timeframes:
NIHR EME start date 01 March 2015. End date 31 Jan 2019.

The latest Patient Information Leaflet is now available.